Protocols
ARCELLX-ACLX-001-DDBCMA Phase I OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-term Safety Follow-up
ARCELLX-ARC-112A-CART-DDBCMA Phase II OPEN TO ACCRUAL
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
BEIGENE-BGB-11417-105 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
CARSGEN-CT053-MM-02 Phase I/II OPEN TO ACCRUAL
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
FATE-FT576-101-MM Phase I OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
IIT-CHHABRA-EMBRACE-MM Phase II OPEN TO ACCRUAL
IIT-Chhabra-EMBRACE-MM: A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (BlenrepĀ®) after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
IIT-DHAKAL-IMPEDE-SGZ-12356 Phase II OPEN TO ACCRUAL
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
MERCK-MK-7684A-004 Phase II OPEN TO ACCRUAL *
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies
NOVARTIS-ADPT07A12101BCMA-CART Phase I OPEN TO ACCRUAL
Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
RAPA-201-RRMM Phase II OPEN TO ACCRUAL
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1(RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma